LANCET:他汀类药物治疗老年人的有效性和安全性如何?

2019-02-02 MedSci MedSci原创

目前已知他汀类药物治疗可大范围降低主要血管事件和血管死亡率,但其在老年人中的有效性和安全性尚不确定。本研究对所有大型他汀类药物试验的数据进行了荟萃分析,以比较他汀类药物在不同年龄段的疗效。在这项荟萃分析中,他汀类药物治疗的随机试验招募至少1000名参与者,且计划治疗时间至少为2年。研究人员分析了22项试验的个体参与者数据(n=134 537)和1项试验(n=12 705)的他汀治疗与对照组的详细汇总数据,以及5项试验(n=39 612)的个体参与者数据(n=39 612)。研究人员将参与者细分为6个年龄组(55岁或以下、56-60岁、61-65岁、66-70岁、71-75岁和75岁以上)。研究人员以LDL胆固醇每降低1.0 mmol/L的比率(RR)来评估对主要血管事件(即主要冠状动脉事件、中风和冠状动脉再血管生成)、特定原因死亡率和癌症发病率的影响。我们使用标准χ2比较比例不同年龄组的风险减少。 研究结果显示,28项试验的186854名参与者中,有14483人(8%)年龄在75岁以上,采用随机分组,中位随访时间为4.9年。总的来说,他汀类药物治疗或更密集的他汀类药物治疗方案每降低1.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=902911, encodeId=623190291192, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Fri Nov 27 18:12:52 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902909, encodeId=0e2690290902, content=<a href='/topic/show?id=2f9525346ca' target=_blank style='color:#2F92EE;'>#他汀类药物#</a> 赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=25346, encryptionId=2f9525346ca, topicName=他汀类药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Fri Nov 27 18:11:43 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829951, encodeId=e47718299519e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 28 13:36:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044536, encodeId=4ede2044536ae, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Dec 23 10:36:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359914, encodeId=fd703599143c, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Mon Feb 04 06:58:44 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359867, encodeId=514335986ea8, content=他汀对老年人的治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 03 08:08:08 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359844, encodeId=1cc6359844c2, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Feb 02 23:02:37 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2020-11-27 飞翔的乌龟

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=902911, encodeId=623190291192, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Fri Nov 27 18:12:52 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902909, encodeId=0e2690290902, content=<a href='/topic/show?id=2f9525346ca' target=_blank style='color:#2F92EE;'>#他汀类药物#</a> 赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=25346, encryptionId=2f9525346ca, topicName=他汀类药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Fri Nov 27 18:11:43 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829951, encodeId=e47718299519e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 28 13:36:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044536, encodeId=4ede2044536ae, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Dec 23 10:36:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359914, encodeId=fd703599143c, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Mon Feb 04 06:58:44 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359867, encodeId=514335986ea8, content=他汀对老年人的治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 03 08:08:08 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359844, encodeId=1cc6359844c2, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Feb 02 23:02:37 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=902911, encodeId=623190291192, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Fri Nov 27 18:12:52 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902909, encodeId=0e2690290902, content=<a href='/topic/show?id=2f9525346ca' target=_blank style='color:#2F92EE;'>#他汀类药物#</a> 赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=25346, encryptionId=2f9525346ca, topicName=他汀类药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Fri Nov 27 18:11:43 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829951, encodeId=e47718299519e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 28 13:36:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044536, encodeId=4ede2044536ae, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Dec 23 10:36:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359914, encodeId=fd703599143c, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Mon Feb 04 06:58:44 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359867, encodeId=514335986ea8, content=他汀对老年人的治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 03 08:08:08 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359844, encodeId=1cc6359844c2, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Feb 02 23:02:37 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-09-28 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=902911, encodeId=623190291192, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Fri Nov 27 18:12:52 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902909, encodeId=0e2690290902, content=<a href='/topic/show?id=2f9525346ca' target=_blank style='color:#2F92EE;'>#他汀类药物#</a> 赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=25346, encryptionId=2f9525346ca, topicName=他汀类药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Fri Nov 27 18:11:43 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829951, encodeId=e47718299519e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 28 13:36:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044536, encodeId=4ede2044536ae, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Dec 23 10:36:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359914, encodeId=fd703599143c, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Mon Feb 04 06:58:44 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359867, encodeId=514335986ea8, content=他汀对老年人的治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 03 08:08:08 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359844, encodeId=1cc6359844c2, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Feb 02 23:02:37 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=902911, encodeId=623190291192, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Fri Nov 27 18:12:52 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902909, encodeId=0e2690290902, content=<a href='/topic/show?id=2f9525346ca' target=_blank style='color:#2F92EE;'>#他汀类药物#</a> 赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=25346, encryptionId=2f9525346ca, topicName=他汀类药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Fri Nov 27 18:11:43 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829951, encodeId=e47718299519e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 28 13:36:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044536, encodeId=4ede2044536ae, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Dec 23 10:36:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359914, encodeId=fd703599143c, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Mon Feb 04 06:58:44 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359867, encodeId=514335986ea8, content=他汀对老年人的治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 03 08:08:08 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359844, encodeId=1cc6359844c2, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Feb 02 23:02:37 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-02-04 lietome24

    认真学习,不断进步,把经验分享给同好。点赞了!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=902911, encodeId=623190291192, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Fri Nov 27 18:12:52 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902909, encodeId=0e2690290902, content=<a href='/topic/show?id=2f9525346ca' target=_blank style='color:#2F92EE;'>#他汀类药物#</a> 赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=25346, encryptionId=2f9525346ca, topicName=他汀类药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Fri Nov 27 18:11:43 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829951, encodeId=e47718299519e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 28 13:36:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044536, encodeId=4ede2044536ae, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Dec 23 10:36:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359914, encodeId=fd703599143c, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Mon Feb 04 06:58:44 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359867, encodeId=514335986ea8, content=他汀对老年人的治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 03 08:08:08 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359844, encodeId=1cc6359844c2, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Feb 02 23:02:37 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-02-03 flysky120

    他汀对老年人的治疗

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=902911, encodeId=623190291192, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Fri Nov 27 18:12:52 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902909, encodeId=0e2690290902, content=<a href='/topic/show?id=2f9525346ca' target=_blank style='color:#2F92EE;'>#他汀类药物#</a> 赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=25346, encryptionId=2f9525346ca, topicName=他汀类药物)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201110/2d55d24dc5fd419d994b7b920c79731b/d3c8bdca983c4af1b90220a8192e353a.jpg, createdBy=e14e5296465, createdName=飞翔的乌龟, createdTime=Fri Nov 27 18:11:43 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829951, encodeId=e47718299519e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 28 13:36:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044536, encodeId=4ede2044536ae, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Dec 23 10:36:00 CST 2019, time=2019-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359914, encodeId=fd703599143c, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Mon Feb 04 06:58:44 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359867, encodeId=514335986ea8, content=他汀对老年人的治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sun Feb 03 08:08:08 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359844, encodeId=1cc6359844c2, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Feb 02 23:02:37 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-02-02 天地飞扬

    了解一下,谢谢分享!

    0

相关资讯

Ann Intern Med:他汀类药物的多种非心血管结局

由此可见,缺乏令人信服的证据表明他汀类药物与非CVD结局之间存在关联,这使得保持目前的建议不变。

Prostate Cancer P D:他汀类药物能够减少经历雄激素阻断治疗糖尿病患者的痴呆风险

雄激素阻断治疗(ADT)已经被报道可以增加痴呆的风险,而他汀类药物的使用可以减少痴呆的风险。最近,有研究人员在接受ADT的2型糖尿病(T2DM)患者中,调查了他汀类药物的使用和痴呆之间的相关性。研究总共包括了在1998年到2013年之间新诊断为PCa的9855名T2DM患者,其中5427名患者因PCa接受了雄激素阻断治疗。在倾向性评分匹配之后,1006名他汀类药物使用者和1006名非他汀类药物使用

JAHA:抗逆转录病毒治疗的艾滋病毒感染者他汀类药物治疗的使用趋势

由此可见,ART方案的变化导致2007年至2014年禁用的他汀类药物使用量下降,但由于含有cobicistat的ART方案的使用增加,这一有利趋势自2015年后有所减弱。

Clin Gastroenterol H:他汀类药物与原发性硬化性胆管炎患者结局改善相关

由此可见,在瑞典患有PSC的基于人群的患者队列中,研究人员将他汀类药物和硫唑嘌呤的使用与死亡以及死亡或肝移植风险降低联系在一起。接触熊去氧胆酸与死亡率降低无关。

Clin Gastroenterol H:诊断肝细胞癌后服用他汀类药物与患者存活情况

由此可见,HCC诊断后服用他汀类药物与HCC患者的死亡率降低有关。

Brit J Cancer:他汀类药物的使用与对侧乳腺癌的风险

由此可见,研究人员发现他汀类药物可降低CBC风险。需要进一步评估以解开长期服用所产生的模棱两可的结果,并确定ER阴性乳腺癌患者是否可以从服用他汀类药物中获益最多。